Suppr超能文献

用于鉴别原发性血小板增多症和继发性血小板增多症的血小板功能测试及炎症标志物

Platelet Function Tests and Inflammatory Markers for the Differentiation of Primary Thrombocytosis and Secondary Thrombocytosis.

作者信息

Kanya Piyapong, Rattarittamrong Ekarat, Wongtakan Ornkamon, Rattanathammethee Thanawat, Chai-Adisaksopha Chatree, Tantiworawit Adisak, Norrasethada Lalita

机构信息

Department of Internal Medicine, Chiang Rai Prachanukroh Hospital, Chiang Rai, Thailand.

Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Rai, Thailand. Email:

出版信息

Asian Pac J Cancer Prev. 2019 Jul 1;20(7):2079-2085. doi: 10.31557/APJCP.2019.20.7.2079.

Abstract

Background: The prognosis and management of primary thrombocytosis (PT) and secondary thrombocytosis (ST) are different. This study aims to evaluate the role of platelet function tests by light transmission platelet aggregometry (LTA), plasma von Willebrand factor antigen (vWF:Ag), ristocetin cofactor activity (vWF:RCo) and inflammatory markers [erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)] for the differentiation between PT and ST. Methods: This prospective study was carried out in patients with platelet counts greater than 450 x 109/L. Primary outcomes were the sensitivity and specificity of platelet function tests by LTA for the differentiation of PT and ST. Secondary outcomes were sensitivity and specificity of ESR, CRP, vWF:Ag, and vWF:RCo for the differentiation of PT and ST. Results: Fifty-two patients were enrolled onto the study of which 26 (50%) had PT. The sensitivity and specificity of epinephrine, collagen, and arachidonic acid (AA) induced abnormal LTA for the differentiation of PT from ST were sensitivity of 50%, 38.5%, 26.9% and specificity of 88.5%, 100%, 100% respectively. The sensitivity and specificity of abnormal ESR, CRP, and either abnormal ESR or CRP in the differentiation of ST from PT were sensitivity of 88.5%, 80.8%, 100% and specificity of 65.4%, 61.5%, 46.2% respectively. The sensitivity and specificity of low vWF:Ag and vWF:RCo in the differentiation of PT from ST were sensitivity of 7.69%, 42.3% and specificity of 100%, 88.5% respectively. Conclusions: Abnormal platelet function determined by LTA with collagen, AA, epinephrine had high specificity ratings enabling the differentiation between PT and ST. vWF:RCo, ESR and CRP levels could be helpful in differentiating between PT and ST.

摘要

背景

原发性血小板增多症(PT)和继发性血小板增多症(ST)的预后及管理有所不同。本研究旨在评估通过光透射血小板聚集试验(LTA)、血浆血管性血友病因子抗原(vWF:Ag)、瑞斯托霉素辅因子活性(vWF:RCo)以及炎症标志物[红细胞沉降率(ESR)、C反应蛋白(CRP)]进行血小板功能检测在区分PT和ST中的作用。方法:本前瞻性研究针对血小板计数大于450×10⁹/L的患者开展。主要结局是LTA血小板功能检测在区分PT和ST方面的敏感性和特异性。次要结局是ESR、CRP、vWF:Ag和vWF:RCo在区分PT和ST方面的敏感性和特异性。结果:52例患者纳入本研究,其中26例(50%)患有PT。肾上腺素、胶原和花生四烯酸(AA)诱导的LTA异常用于区分PT和ST的敏感性分别为50%、38.5%、26.9%,特异性分别为88.5%、100%、100%。ESR异常、CRP异常以及ESR或CRP异常在区分ST和PT方面的敏感性分别为88.5%、80.8%、100%,特异性分别为65.4%、61.5%、46.2%。低vWF:Ag和vWF:RCo在区分PT和ST方面的敏感性分别为7.69%、42.3%,特异性分别为100%、88.5%。结论:LTA检测胶原、AA、肾上腺素时血小板功能异常具有较高的特异性评分,有助于区分PT和ST。vWF:RCo、ESR和CRP水平有助于区分PT和ST。

相似文献

1
Platelet Function Tests and Inflammatory Markers for the Differentiation of Primary Thrombocytosis and Secondary Thrombocytosis.
Asian Pac J Cancer Prev. 2019 Jul 1;20(7):2079-2085. doi: 10.31557/APJCP.2019.20.7.2079.
5
Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count.
Eur J Haematol. 2018 Mar;100(3):286-293. doi: 10.1111/ejh.13012. Epub 2018 Jan 5.
7
The significance of evaluating conventional inflammatory markers in Von Willebrand factor measurement.
Clin Chim Acta. 2007 Jun;381(2):167-70. doi: 10.1016/j.cca.2007.03.007. Epub 2007 Mar 14.
8
Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation.
Thromb Haemost. 2018 Aug;118(8):1397-1408. doi: 10.1055/s-0038-1661393. Epub 2018 Jul 4.
9
Primary thrombocythaemia: a composite approach to diagnosis.
Clin Lab Haematol. 1994 Jun;16(2):139-48. doi: 10.1111/j.1365-2257.1994.tb00400.x.
10
Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
Thromb Res. 2014 Aug;134(2):246-50. doi: 10.1016/j.thromres.2014.04.033. Epub 2014 May 17.

引用本文的文献

1
Erythrocyte sedimentation rate, rather than C-reactive protein, may be the preferred biomarker for hidradenitis suppurativa.
JAAD Int. 2022 May 19;8:47-48. doi: 10.1016/j.jdin.2022.04.005. eCollection 2022 Sep.

本文引用的文献

1
Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count.
Eur J Haematol. 2018 Mar;100(3):286-293. doi: 10.1111/ejh.13012. Epub 2018 Jan 5.
2
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
3
Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.
Mediators Inflamm. 2015;2015:284706. doi: 10.1155/2015/284706. Epub 2015 Oct 11.
4
Myeloproliferative neoplasms and thrombosis.
Blood. 2013 Sep 26;122(13):2176-84. doi: 10.1182/blood-2013-03-460154. Epub 2013 Jul 3.
5
Etiology of thrombocytosis in a general medicine population: analysis of 801 cases with emphasis on infectious causes.
J Clin Med Res. 2012 Dec;4(6):415-23. doi: 10.4021/jocmr1125w. Epub 2012 Nov 11.
7
Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.
Thrombosis. 2011;2011:536062. doi: 10.1155/2011/536062. Epub 2011 Jun 8.
8
How I treat the acquired von Willebrand syndrome.
Blood. 2011 Jun 23;117(25):6777-85. doi: 10.1182/blood-2010-11-297580. Epub 2011 May 3.
9
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
Blood. 2011 Jun 2;117(22):5857-9. doi: 10.1182/blood-2011-02-339002. Epub 2011 Apr 13.
10
How I treat essential thrombocythemia.
Blood. 2011 Feb 3;117(5):1472-82. doi: 10.1182/blood-2010-08-270033. Epub 2010 Nov 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验